CAR T cell therapy for fighting IPF: perspectives on a living drug - PubMed
5 hours ago
- #CAR T cell therapy
- #Fibroblast Activation Protein
- #Idiopathic Pulmonary Fibrosis
- Fibrotic interstitial lung disease (fILD), especially idiopathic pulmonary fibrosis (IPF), is an incurable progressive lung disorder with a poor prognosis.
- Fibroblasts are the main cellular drivers of fibrosis, and current treatments (pirfenidone and nintedanib) cannot significantly slow disease progression.
- Immune dysregulation and alveolitis play a critical role in fibroblast activation and extracellular matrix (ECM) deposition.
- A novel approach involves using genetically engineered CAR T cells to target and eliminate activated fibroblasts expressing fibroblast activation protein (FAP).
- CAR T cells are generated in vivo using mRNA encoding CARs encapsulated in lipid nanoparticles (LNPs).
- This review summarizes CAR T cell strategies for IPF, preclinical studies, clinical trials, and discusses adverse events and limitations of CAR T therapy.